Effect of Human Growth Hormone-Releasing Hormone on the Release of Dynorphin-Like Immunoreactivity, Luteinizing Hormone, and Follicle-Stimulating Hormone from Rat Adenohypophysis in Vitro*

Endocrinology ◽  
1987 ◽  
Vol 120 (2) ◽  
pp. 732-738 ◽  
Author(s):  
W. KNEPEL ◽  
M. SCHWANINGER ◽  
G. WESEMEYER ◽  
K.D. DÖHLER ◽  
J. SANDOW
1990 ◽  
Vol 73 (5) ◽  
pp. 731-735 ◽  
Author(s):  
Lee B. Jacoby ◽  
E. Tessa Hedley-Whyte ◽  
Karen Pulaski ◽  
Bernd R. Seizinger ◽  
Robert L. Martuza

✓ Benign pituitary adenomas are among the most common neurosurgical tumors and account for a diversity of clinical syndromes due to their hormone content and release. To determine whether these tumors arise from a single cell or multiple cells, the authors studied X chromosome inactivation in deoxyribonucleic acid (DNA) isolated from pituitary adenomas in women. Tumors of three different hormonal subtypes were examined. One tumor contained cells immunoreactive for prolactin and human growth hormone; one tumor contained foci immunoreactive for the β-subunits of luteinizing hormone and follicle-stimulating hormone; and the third tumor had no immunoreactive prolactin, human growth hormone, β-subunits of thyroid-stimulating hormone, luteinizing hormone, or follicle-stimulating hormone, or the α-subunit. Analysis of the DNA revealed that, in each of the three pituitary tumors, one X chromosome was active in all cells and one X chromosome was inactive, indicating that each of these tumors was monoclonal in origin. It is concluded that clinically evident pituitary tumors arise from a genetic mutation in a single cell.


FEBS Letters ◽  
1996 ◽  
Vol 394 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Yuichi Fujinaka ◽  
Yutaka Yokogoshi ◽  
Chen-Yu Zhang ◽  
Toshihiro Okura ◽  
Kouki Kitagawa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document